Amendment and Response Application No.: 10/706,791 Attorney Docket No.: WYE-076

Page 2 of 6

## **Amendments to the Claims**

Please replace the previously pending claims with the following claim listing.

- 1-31. (Canceled)
- 32. (Currently amended) A pharmaceutical composition <u>comprising a pharmaceutically acceptable carrier and a nonpeptide small molecule</u> which dissociates a protein complex comprising an insulin-like growth factor (IGF) and an insulin-like growth factor binding protein (IGFBP), wherein the composition is a <u>small molecule formulated to be compatible with an intended route of administration to a subject.</u>
- 33. (Previously presented) The composition of claim 32, wherein the protein complex is further defined as a dimeric complex comprising IGF and IGFBP.
- 34. (Previously presented) The composition of claim 32, wherein the protein complex further comprises an acid labile subunit (ALS), wherein the ration of IGF to IGFBP to ALS is 1:1:1.
- 35. (New) The composition of claim 32, wherein the composition is sterile.
- 36. (New) The composition of claim 32, wherein the composition is formulated to be compatible with oral administration and the pharmaceutically acceptable carrier is edible.